ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2852

Shared and Differing Risk Factors for PsA, Psoriasis, AS, and RA: A Series of Case-control Studies

Alexis Ogdie1, Xingmei Wang 1, Thorvardur J Love 2, Telma Thrastardottir 3, Maureen Dubreuil 4 and Joel Gelfand 5, 1Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 2Faculty of Medicine, University of Iceland, Reykjavik, Iceland, 3University of Iceland, Reykjavik, Iceland, 4Boston University School of Medicine, Boston, 5University of Pennsylvania, Philadelphia, PA

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Ankylosing spondylitis (AS), psoriasis and epidemiology, Psoriatic arthritis, Rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: 5T116: Spondyloarthritis Including Psoriatic Arthritis – Clinical VI: Psoriatic Arthritis Clinical Studies (2852–2857)

Session Type: ACR Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: While a handful of clinical risk factors for the development of inflammatory diseases have been identified, to date, no studies have compared risk factors across multiple inflammatory diseases. The objective of this study was to compare the strength of association of selected potential risk factors for the development of psoriasis, PsA, RA, and AS.

Methods: We performed a series of case-control studies in The Health Improvement Network, a general practitioner database in the United Kingdom. Data between 1994-2015 were included. We identified patients with at least one code for PsA, RA, AS, or psoriasis using validated code lists and matched them to up to ten controls from the general population without these diseases based on age (within 2.5 years), sex, practice and year of diagnosis (controls were required to be in the practice on the diagnosis date and were assigned the same ‘diagnosis date’). We began with an extensive code list of over 100 potential risk factors including common comorbidities, infections, trauma, and a limited number of medications (e.g., statins). Potential risk factors were assessed from the time of enrollment into a THIN practice until the end of the observation period, end of enrollment, or death. Hypothesized risk factors with a prevalence of ≥1% were included in the final models and tables. Univariable logistic regression was used to screen risk factors for association with the disease of interest. Multiple testing was accounted for by setting a p-value of 0.02 as the level of statistical significance. Finally, a multivariable logistic regression model was constructed for each disease using the significant risk factors, stratified by sex.

Results: Demographics of the patient population are shown in Table 1: 7,594 incident PsA cases, 3, 253 incident AS cases, 111,375 incident psoriasis cases, and 28,341 incident RA cases were identified and matched to 75,930, 32,530, 1,113,345, and 282,226 controls respectively. Median age at diagnosis was 48.3 (IQR 38-59), 40.7 (31-54), 43.1 (31-54), and 59.9 (48-71) respectively. Sex was balanced in psoriasis and PsA but more female in RA (68%) and more male in AS (70%). Mean follow up time ranged from 6.4-7.2 years and was slightly longer among controls. In univariable analyses (Table 2), previously identified risk factors in PsA were replicated including obesity, uveitis, and trauma. Smoking was identified as a risk factor in RA as previously described. There were some similar risk factors across all 4 diseases including a positive association between pharyngitis, IBD and uveitis (strongest for AS and PsA) and a similarly strong protective effect of statins. Skin infections were associated with PsA and psoriasis, skin trauma with psoriasis and joint trauma with PsA. Diarrheal infections were associated with PsA and AS. Most risk factors maintained statistical significance in the multivariable models though final models differed slightly by sex.

Conclusion: This set of parallel case-control studies identifies differences between PsA, psoriasis, AS and RA that supports the previous theories of pathophysiologic triggers related to these diseases but also demonstrates some commonalities between diseases.


Disclosure: A. Ogdie, Abbvie, 5, 8, Amgen, 2, 5, 8, BMS, 5, Celgene, 5, 8, Corrona, 5, Lilly, 5, Novartis, 2, 5, 7, 8, Pfizer, 2, 5; X. Wang, None; T. Love, None; T. Thrastardottir, None; M. Dubreuil, None; J. Gelfand, BMS, Boehringer Ingelheim, Janssen Biologics, Novartis Corp, UCB (DSMB), Sanofi, Pfizer Inc, 5, Abbvie, Boehringer Ingelheim,  Janssen, Novartis Corp , Celgene, Ortho Dermatologics, Pfizer Inc., 2, resiquimod, Deputy Editor for the Journal of Investigative Dermatology receiving honoraria from the Society for Investigative Dermatology, 6.

To cite this abstract in AMA style:

Ogdie A, Wang X, Love T, Thrastardottir T, Dubreuil M, Gelfand J. Shared and Differing Risk Factors for PsA, Psoriasis, AS, and RA: A Series of Case-control Studies [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/shared-and-differing-risk-factors-for-psa-psoriasis-as-and-ra-a-series-of-case-control-studies/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/shared-and-differing-risk-factors-for-psa-psoriasis-as-and-ra-a-series-of-case-control-studies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology